Provide an update on the Phase 2 trial
Delivered by the deadline
AI-confirmed · human review in progress Independent AI checks agreed on primary SEC or regulator evidence. Records are now being reviewed by hand, starting with those our customers order.
- Announced
- 10 Nov 2022
- Due
- 30 Jun 2023
- Delivered
- May 2023
- Deadline
- Met
- Late
- Not met
- Today
What the company said
“Larimar expects to provide an update on the Phase 2 trial in Q2 2023”
What we found
Evidence strength A What the grades mean
The company announced top-line data from the 25 mg cohort of its Phase 2 trial in May 2023, which falls within the second quarter of 2023.
-
A Larimar Therapeutics, Inc. 10-Q filed 2023-08-10
“In May 2023, the Company announced top-line data from its completed a 25 mg cohort of a Phase 2, four-week, dose exploration trial of CTI-1601” ✓ confirmed on the page
Market reaction: the shares moved +5.2% against the S&P 500 over the three sessions around the disclosure (9 Aug 2023 to 14 Aug 2023). What this measures
Checked 1 Oct 2026.
Commitment DNA
The structured record of this commitment. Fields the company did not state are left blank rather than guessed.
- Event type
- Product other
- Indicative materiality
- Low rules
- Action
- Provide
- Deliverable
- Phase 2 trial update
- Language
- Expected (“expects”, “plans”)
- In the company’s control
- Medium
- Specificity
- Medium
- Conditional
- Yes: contingent on a review of the study’s 25 mg cohort data by the FDA and the data monitoring committee
- Depends on
- Regulatory
How this entry was checked
- Commitment recordedThe company's words were matched word for word against the filing.
- First checkAn AI model, Gemini (Google), read the company's later filings and recorded the outcome with a quoted passage.
- Second check: agreesA different AI model, Claude (Anthropic), re-read the evidence without being told the outcome and reached the same answer.
Confirmed. This outcome counts towards the company's Kept Score. How verification works
Are you Larimar Therapeutics, Inc.? You can publish an official statement next to this entry, free. Add a statement.
Is something here wrong or out of date? Companies and readers can ask us to check it. Please bring a link to a public source.
Report an error in this entry Reference: KI-C-2022-LRMR-002946 · Corrections policy